

Best-Value Biological Medicine (ADALIMUMAB): Humira® 80 mg


Information for Healthcare Professionals

The MMP recommends Humira® 80 mg as a Best-Value Biological (BVB) Medicine for adalimumab. Prescribing Humira® 80 mg will lead to savings for the health service.

The following presentation of Humira®¹, available on the High Tech Arrangement, is recommended as a best-value biological medicine:

- Humira® 80 mg solution for injection in pre-filled pen

Humira® 80 mg pre-filled pen



- Each pack contains one pre-filled pen (PFP), containing 80 mg of adalimumab in 0.8 ml of solution for injection.
- Each pack also contains two alcohol pads.
- No latex is used in the product or packaging; Humira® 80 mg PFP is therefore suitable for patients with a latex allergy.
- It is supplied as a clear, colourless solution.
- Each PFP is equipped with a 29-gauge needle.
- Humira® 80 mg PFP does not contain citrate.
- Humira® 80 mg PFP has a shelf life of two years.

¹ Please refer to the Summary of Product Characteristics of Humira® available at www.medicines.ie for full prescribing information.

Storage

- Humira® 80 mg PFP should be stored in a refrigerator (2°C - 8°C). It should not be frozen.
- The PFP should be kept in the outer packaging in order to protect it from light.
- A single Humira® 80 mg PFP may be stored at a temperature up to a maximum of 25°C for a period of up to 14 days. The PFP must be protected from light, and discarded if not used within the 14-day period.

Dose Administration

- The patient information leaflet contains a very clear diagrammatic guide on how to administer a dose from the PFP.
- The patient should place the white needle sleeve of the pen straight (90° angle) against the injection site, and firmly push down. Delivery of the dose commences when the patient presses the plum activator button. At this time, the patient will hear a loud click to signal the start of the injection.
- The patient should continue to hold the pen firmly against their skin. The injection is complete when the yellow indicator in the inspection window has stopped moving.
- Once the injection is complete, the PFP should be pulled slowly from the skin. The white needle sleeve will then cover the needle tip.
- Please refer to the Patient Information Leaflet (PIL) for further information.



AbbVie Ireland Limited

AbbVie Ireland Limited provides a patient support service to patients who have been prescribed Humira®. This is provided by Point of Care Limited on behalf of AbbVie Ireland Limited.

The following services are available as part of the patient support service:

- Home visit nurse support: this includes training on the Humira® administration device and education on the biological medicine e.g. storage, travelling tips. This can also be delivered remotely, if required.
- Provision of a patient information pack to include self-injection administration guide and information on travelling with your medication.
- Access to a dedicated patient website.
- Access to a dedicated patient support phonenumber.
- SMS reminder service to aid adherence.
- Sharps management service - this includes the provision of sharps bins and waste collection.
- Provision of a cool bag to support patient travel.
- Provision of faecal calprotectin home test kits to gastroenterology patients.
- Provision of QuantiFeron screening.
- Humira® training device: This is a training pen and is available to healthcare professionals.

To refer a patient who has been prescribed Humira® to the patient support programme or obtain training pens, please contact 1800 200 573 or www.abbviecare.ie

References:

1. Humira® 80 mg solution for injection in pre-filled pen. SmPC and PIL. Last revised 11/10/2022. Accessed at https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf on 29/06/2023.